Akebia Therapeutics, Inc. (AKBA)
0.9747
-0.01
(-0.87%)
USD |
NASDAQ |
Sep 04, 16:00
0.9775
0.00 (0.00%)
After-Hours: 20:00
Akebia Therapeutics Research and Development Expense (Quarterly) : 13.47M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 13.47M |
| March 31, 2026 | 14.48M |
| December 31, 2025 | 26.33M |
| September 30, 2025 | 14.63M |
| June 30, 2025 | 10.70M |
| March 31, 2025 | 9.44M |
| December 31, 2024 | 7.254M |
| September 30, 2024 | 8.124M |
| June 30, 2024 | 7.248M |
| March 31, 2024 | 9.367M |
| December 31, 2023 | 9.472M |
| September 30, 2023 | 12.93M |
| June 30, 2023 | 19.80M |
| March 31, 2023 | 19.29M |
| December 31, 2022 | 32.37M |
| September 30, 2022 | 27.62M |
| June 30, 2022 | 25.61M |
| March 31, 2022 | 43.42M |
| December 31, 2021 | 29.11M |
| September 30, 2021 | 40.00M |
| June 30, 2021 | 36.72M |
| March 31, 2021 | 40.10M |
| December 31, 2020 | 37.06M |
| September 30, 2020 | 46.34M |
| June 30, 2020 | 52.30M |
| Date | Value |
|---|---|
| March 31, 2020 | 80.71M |
| December 31, 2019 | 80.41M |
| September 30, 2019 | 74.51M |
| June 30, 2019 | 85.69M |
| March 31, 2019 | 82.35M |
| December 31, 2018 | 87.11M |
| September 30, 2018 | 70.63M |
| June 30, 2018 | 71.92M |
| March 31, 2018 | 61.40M |
| December 31, 2017 | 68.38M |
| September 30, 2017 | 58.71M |
| June 30, 2017 | 43.75M |
| March 31, 2017 | 60.05M |
| December 31, 2016 | 33.44M |
| September 30, 2016 | 31.24M |
| June 30, 2016 | 30.88M |
| March 31, 2016 | 20.04M |
| December 31, 2015 | 12.48M |
| September 30, 2015 | 15.72M |
| June 30, 2015 | 7.082M |
| March 31, 2015 | 7.433M |
| December 31, 2014 | 7.052M |
| September 30, 2014 | 6.635M |
| June 30, 2014 | 5.513M |
| March 31, 2014 | 6.158M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Emergent BioSolutions, Inc. | 9.20M |
| Exelixis, Inc. | 211.99M |
| ADMA Biologics, Inc. | 6.014M |
| Arcutis Biotherapeutics, Inc. | 20.36M |
| Relay Therapeutics, Inc. | 76.48M |